Vivoryon Therapeutics N.V. · EURONEXT:VVY
Vivoryon Therapeutics — Probiodrug — FY2018 Earnings Presentation
28 slides from Vivoryon Therapeutics's earnings presentation, Mar 28, 2019
Slide 1: The 2018 Full Year Results & Outlook 2019
THE 2018 FULL YEAR RESULTS & OUTLOOK 2019 Halle (Saale), March 28, 2019 Probiodrug AG
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This Presentation has been prepared and issued by Probiodrug AG (the “Company”) and has not been independently verified by any third party. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any proj
Slide 3: Welcome to Probiodrug - The Management Team
WELCOME TO PROBIODRUG - THE MANAGEMENT TEAM - ULRICH DAUER MICHAEL SCHAEFFER PhD / CEO PhD / CBO 20 years experience in the biopharmaceutical industry 18 years of life science industry experience in strategic business development, scientific project and alliance Has held CEO positions in several pri
Slide 4: Agenda
01 HIGHLIGHTS IN 2018 02 PORTFOLIO AGENDA 03 FINANCIALS 2018 04 POST-PERIOD HIGHLIGHTS & OUTLOOK 06 Q&A © Probiodrug AG FY 2018 – March 28, 2019
Slide 5: Highlights in 2018
01 HIGHLIGHTS IN 2018
Slide 6: Highlights and Lowlights 2018
HIGHLIGHTS AND LOWLIGHTS 2018 Highlights Maturing product pipeline and progress towards goal of becoming a leader in the development of innovative drugs for Alzheimer's disease Strategy for the Phase 2b and proof of concept program has been defined and the set-up Phase of SAPHIR 2 Successful P
Slide 7: Portfolio
. Co i 02 PORTFOLIO
Slide 8: Probiodrug's Target Focused Approach: PQ912 Targets QPCT
PROBIODRUG’S TARGET FOCUSED APPROACH: PQ912 TARGETS QPCT Targeting QPCT to inhibit formation of pGlu Abeta APP PLAQUES Amyloid sAPP precursor PQ912 QPCT-inhibition protein Amyloid beta OLIGOMERS (Abeta) Cell β-secretase Cell -secretase Glutaminylcyclase (QPCT) neurotoxic oligomers pGlu-Abeta is fo
Slide 9: AD Therapy Beyond Tau and Abeta: Clearance by PBD-C06
AD THERAPY BEYOND TAU AND Abeta: CLEARANCE OF NEUROTOXIC OLIGOMERS BY PBD-C06 Antibody mediated pGlu-Abeta clearance Plaques Oligomers (pGlu-A/A) (pGlu-A/A) APP neurotoxic oligomers Amyloid sAPP precursor protein Amyloid beta (Abeta) Cell β-secretase Cell -secretase Monomers (pGlu-A) PBD-C06
Slide 10: Why Targeting Abeta Is Not a Good Idea
WHY TARGETING Abeta IS NOT A GOOD IDEA ….but pGlu-Abeta/QPCT is! hallmarks A-beta pGlu-Abeta/QPCT expression pattern brain, plasma, peripheral organs only brain, only in disease upstream enzymes & secretases, meprin only one crucial enzyme: QPCT physiological synaptic function, bbb integrity,
Slide 11: Probiodrug's First-in-Class Drug Pipeline
PROBIODRUG’S FIRST-IN-CLASS DRUG PIPELINE Product Pre-clinical 1 Phase 2a Phase 2b Phase Positive PQ912 results Small molecule QPCT reported inhibitor PBD-C06 pGlu-Abeta specific monoclonal antibody PQ-XXXX 50+ characterized small molecule inhibitors of QPCT/L - for use in other indications © Probio
Slide 12: PQ912 – SAPHIR Clinical Development Strategy in AD
PQ912 – SAPHIR CLINICAL DEVELOPMENT STRATEGY IN AD 1 PHASE 2a PHASE 2b PHASE 3 PHASE Comprehensive single Pilot double blind study Clinical proof of concept Confirmation of Phase 2b and multiple dose in target AD population study program powered results (if required) studies for cognitive endpoints
Slide 13: SAPHIR Phase 2b Trial Development Strategy
SAPHIR PHASE 2B TRAIL DEVELOPMENT STRATEGY EU STUDY US STUDY Cognitive and functional endpoints Complementary to EU study create a solid base for Phase 3 program with longer treatment duration Innovative design with sufficiently long Powered for cognition read-out treatment to enable predictive cogn
Slide 14: Financials 2018
03 FINANCIALS 2018
Slide 15: Share
SHARE KEY INFORMATION SHAREHOLDER STRUCTURE SHARE PRICE ISIN: DE0007921835 % 180 WKN: 792183 160 140 Ticker symbol: PBD 120 Types of shares: Bearer shares 100 80 Number of shares 8,208,009 60 Euronext Stock exchange: 40 Amsterdam 20 Liquidity provider: Kempen & Co. 0 1/1/18 2/1/18 3/1/18 4/1/18 5/1/
Slide 16: Key Financial Highlights (P&L): According to IFRS
KEY FINANCIAL HIGHLIGHTS (P&L): ACCORDING TO IFRS IN €k 2018 2017 % Research and development expenses -4,836 -7,454 -35,1 General and administrative expenses -2,891 -2,511 15,1 Other operating income 29 4 86,2 Operating loss -7,698 -9,961 -22,7 Finance income 2 862 -99,8 Finance expenses -41 -12 70,
Slide 17: Key Financial Figures (According to IFRS)
KEY FINANCIAL FIGURES (ACCORDING TO IFRS) In €k Dec 31, 2018 Dec 31, 2017 Earnings, Financial and Net Assets Position Operating loss -7,698 -9,961 Finance income/loss -39 850 Income tax gain 0 1,102 Net loss for the period -7,737 -8,009 Equity (end of the year) 1,230 8,923 Equity ratio (end of the y
Slide 18: Post-Period Highlights & Outlook
04 POST-PERIOD HIGHLIGHTS & OUTLOOK
Slide 19: NIH Grants 15M US-$ to Support US Phase 2b Trial
NIH GRANTS 15M US-$ TO SUPPORT US PHASE 2B TRIAL © Probiodrug AG FY 2018 – March 28, 2019 19
Slide 20: First-in-Class Small Molecules as Myeloid Immune-Checkpoint Inhibitors
FIRST-IN-CLASS SMALL MOLECULES AS MYELOID IMMUNE- CHECKPOINT INHIBITORS augmenting cancer immunotherapy by blocking the CD47-SIRPa axis with QPCTL inhibitors
Slide 21: QPCTL: A Novel Target for Cancer Immunotherapy
QPCTL: A NOVEL TARGET FOR CANCER IMMUNOTHERAPY interference with the CD47-SIRPα CORE DATA interaction potently synergizes with cancer therapeutic antibodies used to opsonize tumor cells. QPCTL inhibition enhances antibody-dependent cellular phagocytosis tumor cells. Van den Berg et al. , PNAS , 2011
Slide 22: Myeloid Immune-Checkpoint Inhibition: Probiodrug's Unique Position
MYELOID IMMUNE-CHECKPOINT INHIBITON: PROBIODRUG‘S UNIQUE POSITION Lead compound PQ912 did not induce anemia and is well tolerated in young and elderly*. First-in-class small molecule approach circumvents antibody sink problem caused by red blood cells. Probiodrug owns a number of compounds wit
Slide 23: Outlook
OUTLOOK First Patient in SAPHIR 2 2 IND-Filing for PQ912 0 1 Strengthen financial basis through 9 Pharma Partnership or Capital Market Exploit potential of unique patent estate for QPCT/L inhibitors in immune oncology * Pre-clinical proof of Principle © Probiodrug AG FY 2018 – March 28, 2019 Please
Slide 24: Outlook
OUTLOOK Mid-term focus of Probiodrug’s business activities Execution of the Phase 2b clinical study program for PQ912, Continuing partner discussions with PBD-C06, Conclusion of one or more industrial partnerships, Further scientific analysis of potential second indications for the use of QC
Slide 25: Financial Calendar 2019
FINANCIAL CALENDAR 2019 Please note: Subject to change, for actual information please see Homepage © Probiodrug AG FY 2018 – March 28, 2019 25
Slide 26: Q&A
05 Q&A
Slide 27: Thank You!
THANK YOU!
Slide 28: Contact
CONTACT Probiodrug AG Weinbergweg 22 06120 Halle (Saale) Germany +49 (0)345 - 555 99 00 [email protected] www.probiodrug.com © Probiodrug AG FY 2018 – March 28, 2019 28